Clinical Trial Update: Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial (SIDEC) is evaluating subcutaneous immunoglobulin for de novo Chronic Inflammatory Demyelinating Polyneuropathy. The study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Subcutaneous Immunoglobulin (SCIG) (immunoglobulin G (IgG))

Snippet

Sponsor: University of Aarhus | Conditions: CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 4 | Status: RECRUITING